Details of the Drug

General Information of Drug (ID: DMR23M1)

Drug Name

Mapracorat

Synonyms

BOL-303242X; SEGRA, Intendis; SEGRA, Schering AG; ZK-216348; ZK-238587; ZK-245186; Mapracorat (ophthalmic, ocular inflammation); Mapracorat Ophthalmic Suspension, Bausch & Lomb; SEGRA (atopic dermatitis), Bayer; Selective glucocorticoid receptor agonists (SEGRA) Bayer Schering/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA) Schering AG/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA), Schering AG; Selective glucocorticoid receptor agonists (dermatology), Schering AG; Mapracorat (dermatological, atopic dermatitis), Intendis; SEGRA (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonist (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonists (dermatological, eczema), Intendis; Suppressor of pro-inflammatory mediators (eczema), Intendis; BOL-303242-X Ophthalmic Suspension, Bausch & Lomb; Mapracorat (ophthalmic, ocular inflammation), Bausch & Lomb; ZK-245186 (ophthalmic), Bausch & Lomb

Indication

Disease Entry	ICD 11	Status	REF
Ocular disease	1F00.1Z	Phase 3	[1], [2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

462.5

Topological Polar Surface Area (xlogp)

6.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Chemical Identifiers

Formula: C25H26F4N2O2
IUPAC Name: (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[[(2-methylquinolin-5-yl)amino]methyl]pentan-2-ol
Canonical SMILES: CC1=NC2=C(C=C1)C(=CC=C2)NC[C@](CC(C)(C)C3=CC(=CC4=C3OCC4)F)(C(F)(F)F)O
InChI: InChI=1S/C25H26F4N2O2/c1-15-7-8-18-20(5-4-6-21(18)31-15)30-14-24(32,25(27,28)29)13-23(2,3)19-12-17(26)11-16-9-10-33-22(16)19/h4-8,11-12,30,32H,9-10,13-14H2,1-3H3/t24-/m1/s1
InChIKey: VJGFOYBQOIPQFY-XMMPIXPASA-N

Cross-matching ID

PubChem CID: 24795088
CAS Number: 887375-26-0
DrugBank ID: DB12041
TTD ID: D01IUS

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Agonist	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8643).
2	ClinicalTrials.gov (NCT01298752) Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery. U.S. National Institutes of Health.
3	Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol. 2009 Oct;158(4):1088-103.
4	Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
7	Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60.
8	Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22.
9	PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
10	The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.